Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTEct-MS (temelimab following rituximab in RMS) study
MS Virtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13 https://geneuro.ch/data/news/P0239-Piehl.pdf